Structurally IGF-1 LR3 is different from its patent compound because of the presence of Arginine instead of glutamic acid at the 3rd position of its amino acid sequence and 13 extra amino acids at the N-terminus
Currently, Wegovy is FDA approved for the following: Children ages 12 years or older with a body mass index (BMI) at or above the 95th percentile for their sex and age Adults with a BMI at or above 30 Adults with a BMI at or above 27 and at least one weight-related health condition, such as heart disease, diabetes, high blood pressure, or sleep apnea Adults with a BMI at or above 27 with established cardiovascular disease and a risk of major adverse cardiovascular events (like heart attack or stroke) Adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis Note that there are slightly different prescribing rules for Wegovy pills versus Wegovy injections
For more information on changes to sampling methods over time, please consult the extended methods ( which describes changes made in each years survey
Market Exclusions The scope excludes glucoselowering therapies that do not act via the GLP1 receptor (such as SGLT2 inhibitors, insulin, or DPP4 inhibitors), diagnostic tests, and devices
